Provides hands-on, end-to-end support for select translational, life sciences research projects with the goal of launching them into investable startup ventures.
BiomeSense is developing a fully automated biosensor for low-cost, scalable microbiome testing. The device will solve the cost and patient adherence problems with current testing methods, making longitudinal sampling routine. This will exponentially improve the data available to researchers, accelerating the microbiome’s integration into therapeutic development, clinical practice, and more. BiomeSense… Read More
AVnovum is developing a new class of antimicrobial therapy, AVpeptides, that maintain healthy fungal microbiomes by preventing virulence and infection. AVpeptides work through mechanisms that specifically target virulent but not health-promoting microbes. AVnovum is driven by a diverse team of research scientists and advisors from the University of Chicago Medical… Read More
Oxalo Therapeutics is developing first-in-class therapeutics to treat rare renal diseases and prevent recurrent kidney stones. University of Chicago assistant professor of medicine Hatim Hassan, MD, PhD, studies kidney disease and his research led him to leverage the microbiome to create new ways to prevent kidney stones. Read More
Seurat Therapeutics is based on years of research by Richard Kraig, MD, PhD, at the University of Chicago that targets a naturally-derived cure for migraines aimed at the root cause rather than alleviating the symptoms. Based at the Polsky Center for Entrepreneurship and Innovation’s Polsky Exchange, the team… Read More
ClostraBio is dedicated to understanding and treating food allergies and other disease of the immune system. Founded in 2016 by Cathryn R. Nagler, PhD and Jeffrey A. Hubbell, PhD, ColstraBio is making strides in the discovery and development of new therapeutics that modulate the protective… Read More